Navigation Links
Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
Date:6/8/2012

MIAMI, June 8, 2012 /PRNewswire/ -- At this year's SNM Annual Meeting, June 9-13, Royal Philips Electronics (NYSE: PHG, AEX: PHI) is highlighting its portfolio of nuclear medicine (NM) applications for IntelliSpace Portal, adding to its existing portfolio of CT, MR and multimodality applications. The full suite of NM applications will now offer comprehensive processing and review capabilities at a level normally reserved exclusively for dedicated NM workstations. The company will also showcase solutions designed to increase diagnostic confidence, enhance patient comfort, augment physician confidence, simplify clinical workflow and reduce lifecycle costs. 

"The nuclear medicine applications portfolio for the IntelliSpace Portal is designed to help nuclear medicine professionals improve their workflow and evaluate a patient's progress," said Jay Mazelsky, senior vice president and general manager, Philips Computed Tomography and Nuclear Medicine. "As a leader in nuclear medicine, Philips strives to provide solutions for our customers that improve collaboration in order to provide enhanced care for patients."   

The NM applications portfolio for IntelliSpace Portal now allows NM technologists and physicians to process, review and analyze images from SPECT, SPECT/CT, PET/CT and PET/MR, and then share images and findings with referring physicians using advanced collaboration tools. The clinical applications on IntelliSpace Portal can be accessed from virtually any networked computer – allowing clinicians the flexibility to collaboratively assess results at the hospital or remotely.  

"The IntelliSpace Portal nuclear medicine features have drastically changed the way we treat patients," said Janusz Kikut, MD, director of nuclear medicine and PET/CT, Fletcher Allen Health Care, Burlington, Vt. "The features now allow us to better monitor change in disease status using the nuclear medicine imaging modalities that are often important to diagnosis. And, since we can access IntelliSpace Portal away from our campus, we've been able to improve our workflow with radiologists and seamlessly communicate the nuclear medicine results to referring physicians."

Since the IntelliSpace Portal is built on a scalable server-client platform, it also offers the flexibility to efficiently add concurrent users as well as new clinical applications. This virtually eliminates the need for costly and time consuming upgrades across multiple workstations. The IntelliSpace Portal can also interface with Philips or non-Philips picture archiving and communication systems (PACS), providing direct access to the comprehensive suite of NM review and processing applications.

Key NM application features include:

  • NM Review: A comprehensive and integrated review application for all types of NM and fused data, e.g., planar (dynamic, static, gated), SPECT (includes gated SPECT), SPECT/CT, PET/CT, PET/MR
  • NM Processing Application Suite: A comprehensive suite of organ-specific applications
  • Astonish Reconstruction: Boost departmental efficiency with cardiac imaging in half the time
  • Multimodality Tumor Tracking: Supports side-by-side comparisons of serial CT, MR and PET studies in order to assess the effectiveness of cancer treatment
  • Prefetch: Determines studies which need to be compared to previous scans and makes them available on Portal for review and comparison
  • Collaboration Viewer: Allows for fast and efficient processing of SPECT, SPECT/CT and PET/CT images along with collaboration between medical specialists and referrals

Philips is a leader in nuclear medicine imaging and delivers advanced solutions that meet the challenges clinicians often face. In addition to IntelliSpace Portal, Philips will also feature:

  • Ingenuity TF PET/MR: Philips' first commercially available whole-body positron emission tomography/magnetic resonance (PET/MR) imaging system which Philips began marketing in the U.S. in November 2011
  • TruFlight Select PET/CT: Philips' first economical PET/CT system equipped with its premium time-of-flight (TOF) technology, Astonish TF. Astonish TF is designed to enhance image quality by reducing image artifacts to help clinicians detect and locate lesions, increase diagnostic confidence and preserve healthy tissue during treatment
  • BrightView XCT with Full Iterative Technology (FIT): FIT for SPECT and CT uses advanced algorithms for exceptional images   

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 122,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.6 billion in 2011, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.


'/>"/>
SOURCE Royal Philips Electronics Trade Show: SNM Annual Meeting
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. When Bystanders Become Lifesavers - Launch of Philips SaveLives.net
2. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
3. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
4. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
5. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
6. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
7. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
8. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting
11. Young Innovations, Inc. Board Of Directors Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/28/2017)... LONDON , March 28, 2017  "US ... insight on the various indicators and trend analysis ... generics drugs in mainstream pharmaceutical market in US. ... responsible for the growth on cancer generics drugs ... resulted in saving of billions of dollars for ...
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
Breaking Medicine Technology:
(Date:3/28/2017)... NEW YORK (PRWEB) , ... March 28, 2017 ... ... development, NTX Technology™, is the first technology to directly address the resolution to ... Organization. NTX Technology™ is a patented compound of FDA and TTB approved ingredients ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
Breaking Medicine News(10 mins):